244 related articles for article (PubMed ID: 17976390)
21. Bone marrow expression of poly(ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion.
Terashima T; Kojima H; Chan L
FASEB J; 2012 Jan; 26(1):295-308. PubMed ID: 21978940
[TBL] [Abstract][Full Text] [Related]
22. Na+/H+ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats.
Lupachyk S; Watcho P; Shevalye H; Vareniuk I; Obrosov A; Obrosova IG; Yorek MA
Am J Physiol Endocrinol Metab; 2013 Aug; 305(3):E396-404. PubMed ID: 23736542
[TBL] [Abstract][Full Text] [Related]
23. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy.
Negi G; Kumar A; Sharma SS
Biochem Biophys Res Commun; 2010 Jan; 391(1):102-6. PubMed ID: 19900402
[TBL] [Abstract][Full Text] [Related]
24. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
Obrosova IG; Pacher P; Szabó C; Zsengeller Z; Hirooka H; Stevens MJ; Yorek MA
Diabetes; 2005 Jan; 54(1):234-42. PubMed ID: 15616034
[TBL] [Abstract][Full Text] [Related]
25. Diabetes-induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain.
Ved N; Da Vitoria Lobo ME; Bestall SM; L Vidueira C; Beazley-Long N; Ballmer-Hofer K; Hirashima M; Bates DO; Donaldson LF; Hulse RP
J Physiol; 2018 Aug; 596(16):3675-3693. PubMed ID: 29774557
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model.
Sweitzer SM; Medicherla S; Almirez R; Dugar S; Chakravarty S; Shumilla JA; Yeomans DC; Protter AA
Pain; 2004 Jun; 109(3):409-419. PubMed ID: 15157702
[TBL] [Abstract][Full Text] [Related]
27. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats.
Stevens MJ; Li F; Drel VR; Abatan OI; Kim H; Burnett D; Larkin D; Obrosova IG
J Pharmacol Exp Ther; 2007 Jan; 320(1):458-64. PubMed ID: 17021258
[TBL] [Abstract][Full Text] [Related]
28. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice.
Vareniuk I; Pavlov IA; Drel VR; Lyzogubov VV; Ilnytska O; Bell SR; Tibrewala J; Groves JT; Obrosova IG
Exp Neurol; 2007 Jun; 205(2):425-36. PubMed ID: 17475250
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy.
Sharma SS; Kumar A; Kaundal RK
Life Sci; 2008 Mar; 82(11-12):570-6. PubMed ID: 18262571
[TBL] [Abstract][Full Text] [Related]
30. Macrophage depletion delays progression of neuropathic pain in diabetic animals.
Mert T; Gunay I; Ocal I; Guzel AI; Inal TC; Sencar L; Polat S
Naunyn Schmiedebergs Arch Pharmacol; 2009 May; 379(5):445-52. PubMed ID: 19139849
[TBL] [Abstract][Full Text] [Related]
31. Poly (ADP-ribose) polymerase mediates diabetes-induced retinal neuropathy.
Mohammad G; Siddiquei MM; Abu El-Asrar AM
Mediators Inflamm; 2013; 2013():510451. PubMed ID: 24347828
[TBL] [Abstract][Full Text] [Related]
32. Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes.
Kellogg AP; Wiggin TD; Larkin DD; Hayes JM; Stevens MJ; Pop-Busui R
Diabetes; 2007 Dec; 56(12):2997-3005. PubMed ID: 17720896
[TBL] [Abstract][Full Text] [Related]
33. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.
Drel VR; Mashtalir N; Ilnytska O; Shin J; Li F; Lyzogubov VV; Obrosova IG
Diabetes; 2006 Dec; 55(12):3335-43. PubMed ID: 17130477
[TBL] [Abstract][Full Text] [Related]
34. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.
Obrosova IG; Drel VR; Pacher P; Ilnytska O; Wang ZQ; Stevens MJ; Yorek MA
Diabetes; 2005 Dec; 54(12):3435-41. PubMed ID: 16306359
[TBL] [Abstract][Full Text] [Related]
35. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.
Obrosova IG; Stavniichuk R; Drel VR; Shevalye H; Vareniuk I; Nadler JL; Schmidt RE
Am J Pathol; 2010 Sep; 177(3):1436-47. PubMed ID: 20724598
[TBL] [Abstract][Full Text] [Related]
36. Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease.
Shevalye H; Maksimchyk Y; Watcho P; Obrosova IG
Biochim Biophys Acta; 2010 Nov; 1802(11):1020-7. PubMed ID: 20621183
[TBL] [Abstract][Full Text] [Related]
37. Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy.
Asano S; Himeno T; Hayami T; Motegi M; Inoue R; Nakai-Shimoda H; Miura-Yura E; Morishita Y; Kondo M; Tsunekawa S; Kato Y; Kato K; Naruse K; Nakamura J; Kamiya H
J Diabetes Res; 2019; 2019():2756020. PubMed ID: 31828158
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
40. Combination strategy of PARP inhibitor with antioxidant prevent bioenergetic deficits and inflammatory changes in CCI-induced neuropathy.
Komirishetty P; Areti A; Gogoi R; Sistla R; Kumar A
Neuropharmacology; 2017 Feb; 113(Pt A):137-147. PubMed ID: 27712995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
